Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting - Seite 2

The two Phase 3 pivotal study oral presentations will take place on Thursday, February 18, 2016, from 4:45 to 5:15 pm Hawaii-Aleutian Standard Time (HAST) during Session A: Oral Abstracts – Late Effects, Supportive Care and Quality of Life, in Exhibit Hall 3 at the Hawaii Convention Center:

• Presentation 7, Paul G. Richardson, M.D., "Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial." Dr. Richardson and co-authors will present data from an analysis of Day +100 survival (primary endpoint) and complete response (key secondary endpoint) data from a pivotal Phase 3 study of defibrotide in the treatment of VOD with MOD following HSCT. Dr. Richardson is the lead investigator and director of clinical research at the LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and the RJ Corman Professor of Medicine at Harvard Medical School.
• Presentation 8, Selim Corbacioglu, M.D., "Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Sub-analysis Data from an Open-Label, Phase 3, Randomized Trial." Dr. Corbacioglu, of the University of Regensburg, Germany, will present results from a sub-analysis of data from an open-label, randomized, Phase 3 pediatric trial of defibrotide for the prophylaxis of VOD, including patients with specific VOD / SOS risk factors.

The third oral presentation will take place on Sunday, February 21 from 4:45 to 5:00 pm HAST during Session L:  Oral Abstracts – Late Effects, Supportive Care and Quality of Life, in room #316 ABC at the Hawaii Convention Center:

• Presentation 83, Paul G. Richardson, M.D., "Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival." Dr. Richardson will present results from an exploratory post-hoc analysis of data from an expanded access treatment of VOD / SOS study to evaluate the timing of defibrotide initiation post VOD diagnosis and impact on Day +100 survival following HSCT.

The 10 posters will be presented in the poster sessions in Exhibit Hall 3 at the Hawaii Convention Center. The following will be presented on Thursday, February 18 from 6.45 to 7:45 pm HAST: